NKTR - Nektar Therapeutics GAAP EPS of -$0.49 beats by $0.21 revenue of $24.8M misses by $0.09M
Nektar Therapeutics press release (NASDAQ:NKTR): Q1 GAAP EPS of -$0.49 beats by $0.21. Revenue of $24.8M (+4.9% Y/Y) misses by $0.09M. Cash and investments in marketable securities at March 31, 2022 were approximately $704.4 million as compared to $798.8 million at December 31, 2021, which is expected to support operations into 2025.
For further details see:
Nektar Therapeutics GAAP EPS of -$0.49 beats by $0.21, revenue of $24.8M misses by $0.09M